Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study

BACKGROUND: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, there had been no direct comparative phase III trial...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ther Adv Med Oncol
Päätekijät: Chida, Keigo, Kotani, Daisuke, Nakamura, Yoshiaki, Kawazoe, Akihito, Kuboki, Yasutoshi, Shitara, Kohei, Kojima, Takashi, Taniguchi, Hiroya, Watanabe, Jun, Endo, Itaru, Yoshino, Takayuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064512/
https://ncbi.nlm.nih.gov/pubmed/33959196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211009143
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia